कृपया अन्य खोज का प्रयास करें
MedRx Co., Ltd, a pharmaceutical formulation development company, provides pharmaceutical drugs based on the transdermal absorption system in Japan. The company develops medicines based on Ionic liquid transdermal system (ILTS) and Nano-sized Colloid Transdermal System (NCTS); and researches and develops painless transdermal administration system for vaccines, nucleic acid medicines, protein medicines, etc. Its products pipeline includes MRX-4TZT, which is in phase I clinical trials for the treatment of spastic paralysis; MRX-9FLT that is in phase I clinical trials to treat chronic, cancer, and severe pain; and MRX-7MLL and MRX-6LDT that is in pre-clinical trials to treat Alzheimer’s disease and chronic pain, as well as MRX-5LBT that has completed the clinical trials for the treatment of postherpetic nerve pain. MedRx Co., Ltd was incorporated in 2002 and is headquartered in Higashikagawa, Japan.
नाम | आयु | पहले | शीर्षक |
---|---|---|---|
Kunio Iwatani | 81 | 2015 | Independent External Director |
Masayoshi Matsumura | 79 | 2002 | Chairman |
Hiroshi Akitomo | 62 | 2005 | Manager of Development Department and Director |
Keiko Yamasaki | 73 | 2002 | Manager of Quality Control Department and Director |
Ken Fujioka | - | 2020 | GM of Business Administration Department & Director |
Yonehiro Matsumura | 53 | 2013 | President, CEO & Representative Director |
Hidetoshi Hamamoto | 54 | 2011 | Manager of Research Department and Director |
Hiroshi Danno | 55 | 2007 | External Auditor |
क्या आप सच में %USER_NAME% को ब्लॉक करना चाहते हैं?
ऐसा करके, आप और %USER_NAME% नहीं देख पाएंगे किसी अन्य के Investing.com की पोस्ट में से कोई भी।
%USER_NAME% को सफलतापूर्वक आपकी ब्लॉक सूची में जोड़ लिया गया है
क्योंकि आपने इस व्यक्ति को अनब्लॉक कर दिया है, आपको ब्लॉक को रिन्यू करने से पहले 48 घंटे प्रतीक्षा करनी होगी।
मुझे लगता है कि यह टिपण्णी:
धन्यवाद!
आपकी रिपोर्ट समीक्षा के लिए हमारे मॉडरेटर को भेजी गई है